BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 31243771)

  • 21. Association of Cytogenetics Aberrations and
    Muñoz-Novas C; González-Gascón-Y-Marín I; Figueroa I; Sánchez-Paz L; Pérez-Carretero C; Quijada-Álamo M; Rodríguez-Vicente AE; Infante MS; Foncillas MÁ; Landete E; Churruca J; Marín K; Ramos V; Sánchez Salto A; Hernández-Rivas JÁ
    Glob Med Genet; 2024 Jan; 11(1):59-68. PubMed ID: 38348157
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical, immunophenotypic, and molecular profiling of trisomy 12 in chronic lymphocytic leukemia and comparison with other karyotypic subgroups defined by cytogenetic analysis.
    Athanasiadou A; Stamatopoulos K; Tsompanakou A; Gaitatzi M; Kalogiannidis P; Anagnostopoulos A; Fassas A; Tsezou A
    Cancer Genet Cytogenet; 2006 Jul; 168(2):109-19. PubMed ID: 16843100
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Comparison of four prognostic scoring system in patients with early asymptomatic chronic lymphocytic leukemia patients].
    Sha YQ; Shen H; Wu W; Xia Y; Miao Y; Cao L; Wang L; Fan L; Xu W; Li JY; Zhu HY
    Zhonghua Xue Ye Xue Za Zhi; 2021 Oct; 42(10):834-839. PubMed ID: 34788923
    [No Abstract]   [Full Text] [Related]  

  • 24. Distinct immunoglobulin heavy chain variable region gene repertoire and lower frequency of del(11q) in Taiwanese patients with chronic lymphocytic leukaemia.
    Huang YJ; Kuo MC; Chang H; Wang PN; Wu JH; Huang YM; Ma MC; Tang TC; Kuo CY; Shih LY
    Br J Haematol; 2019 Oct; 187(1):82-92. PubMed ID: 31230372
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biomarkers in chronic lymphocytic leukemia: Clinical applications and prognostic markers.
    Amaya-Chanaga CI; Rassenti LZ
    Best Pract Res Clin Haematol; 2016 Mar; 29(1):79-89. PubMed ID: 27742074
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High-throughput sequencing for the identification of NOTCH1 mutations in early stage chronic lymphocytic leukaemia: biological and clinical implications.
    Lionetti M; Fabris S; Cutrona G; Agnelli L; Ciardullo C; Matis S; Ciceri G; Colombo M; Maura F; Mosca L; Gentile M; Recchia AG; Ilariucci F; Musolino C; Molica S; Di Raimondo F; Cortelezzi A; Rossi D; Gaidano G; Morabito F; Ferrarini M; Neri A
    Br J Haematol; 2014 Jun; 165(5):629-39. PubMed ID: 24579978
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Routine sequencing in CLL has prognostic implications and provides new insight into pathogenesis and targeted treatments.
    Hu B; Patel KP; Chen HC; Wang X; Wang F; Luthra R; Routbort MJ; Kanagal-Shamanna R; Medeiros LJ; Yin CC; Zuo Z; Ok CY; Loghavi S; Tang G; Tambaro FP; Thompson P; Burger J; Jain N; Ferrajoli A; Bose P; Estrov Z; Keating MJ; Wierda WG
    Br J Haematol; 2019 Jun; 185(5):852-864. PubMed ID: 30924136
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mutational and cytogenetic analyses of 188 CLL patients with trisomy 12: A retrospective study from the French Innovative Leukemia Organization (FILO) working group.
    Roos-Weil D; Nguyen-Khac F; Chevret S; Touzeau C; Roux C; Lejeune J; Cosson A; Mathis S; Feugier P; Leprêtre S; Béné MC; Baron M; Raynaud S; Struski S; Eclache V; Sutton L; Lesty C; Merle-Béral H; Cymbalista F; Ysebaert L; Davi F; Leblond V;
    Genes Chromosomes Cancer; 2018 Nov; 57(11):533-540. PubMed ID: 30203893
    [TBL] [Abstract][Full Text] [Related]  

  • 29. EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia.
    Young E; Noerenberg D; Mansouri L; Ljungström V; Frick M; Sutton LA; Blakemore SJ; Galan-Sousa J; Plevova K; Baliakas P; Rossi D; Clifford R; Roos-Weil D; Navrkalova V; Dörken B; Schmitt CA; Smedby KE; Juliusson G; Giacopelli B; Blachly JS; Belessi C; Panagiotidis P; Chiorazzi N; Davi F; Langerak AW; Oscier D; Schuh A; Gaidano G; Ghia P; Xu W; Fan L; Bernard OA; Nguyen-Khac F; Rassenti L; Li J; Kipps TJ; Stamatopoulos K; Pospisilova S; Zenz T; Oakes CC; Strefford JC; Rosenquist R; Damm F
    Leukemia; 2017 Jul; 31(7):1547-1554. PubMed ID: 27890934
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical monoclonal B lymphocytosis versus Rai 0 chronic lymphocytic leukemia: A comparison of cellular, cytogenetic, molecular, and clinical features.
    Morabito F; Mosca L; Cutrona G; Agnelli L; Tuana G; Ferracin M; Zagatti B; Lionetti M; Fabris S; Maura F; Matis S; Gentile M; Vigna E; Colombo M; Massucco C; Recchia AG; Bossio S; De Stefano L; Ilariucci F; Musolino C; Molica S; Di Raimondo F; Cortelezzi A; Tassone P; Negrini M; Monti S; Rossi D; Gaidano G; Ferrarini M; Neri A
    Clin Cancer Res; 2013 Nov; 19(21):5890-900. PubMed ID: 24036852
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data.
    International CLL-IPI working group
    Lancet Oncol; 2016 Jun; 17(6):779-790. PubMed ID: 27185642
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia.
    Nadeu F; Delgado J; Royo C; Baumann T; Stankovic T; Pinyol M; Jares P; Navarro A; Martín-García D; Beà S; Salaverria I; Oldreive C; Aymerich M; Suárez-Cisneros H; Rozman M; Villamor N; Colomer D; López-Guillermo A; González M; Alcoceba M; Terol MJ; Colado E; Puente XS; López-Otín C; Enjuanes A; Campo E
    Blood; 2016 Apr; 127(17):2122-30. PubMed ID: 26837699
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The mutational landscape of small lymphocytic lymphoma compared to non-early stage chronic lymphocytic leukemia.
    Martínez-Trillos A; Pinyol M; Delgado J; Aymerich M; Rozman M; Baumann T; González-Díaz M; Hernández JM; Alcoceba M; Muntañola A; Terol MJ; Navarro B; Giné E; Jares P; Beà S; Navarro A; Colomer D; Nadeu F; Colado E; Payer AR; García-Cerecedo T; Puente XS; López-Otin C; Campo E; López-Guillermo A; Villamor N
    Leuk Lymphoma; 2018 Oct; 59(10):2318-2326. PubMed ID: 29115891
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Landscape of NOTCH1 mutations and co-occurring biomarker alterations in chronic lymphocytic leukemia.
    Jelloul FZ; Yang R; Garces S; Kanagal-Shamanna R; Ok CY; Loghavi S; Routbort MJ; Zuo Z; Yin CC; Floyd K; Bassett RL; Wierda W; Jain N; Thompson P; Luthra R; Medeiros LJ; Patel KP
    Leuk Res; 2022 May; 116():106827. PubMed ID: 35430388
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recurrent mutations refine prognosis in chronic lymphocytic leukemia.
    Baliakas P; Hadzidimitriou A; Sutton LA; Rossi D; Minga E; Villamor N; Larrayoz M; Kminkova J; Agathangelidis A; Davis Z; Tausch E; Stalika E; Kantorova B; Mansouri L; Scarfò L; Cortese D; Navrkalova V; Rose-Zerilli MJ; Smedby KE; Juliusson G; Anagnostopoulos A; Makris AM; Navarro A; Delgado J; Oscier D; Belessi C; Stilgenbauer S; Ghia P; Pospisilova S; Gaidano G; Campo E; Strefford JC; Stamatopoulos K; Rosenquist R;
    Leukemia; 2015 Feb; 29(2):329-36. PubMed ID: 24943832
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An extensive molecular cytogenetic characterization in high-risk chronic lymphocytic leukemia identifies karyotype aberrations and TP53 disruption as predictors of outcome and chemorefractoriness.
    Rigolin GM; Formigaro L; Cavallari M; Quaglia FM; Lista E; Urso A; Guardalben E; Martinelli S; Saccenti E; Bassi C; Lupini L; Bardi MA; Volta E; Tammiso E; Melandri A; Negrini M; Cavazzini F; Cuneo A
    Oncotarget; 2017 Apr; 8(17):28008-28020. PubMed ID: 28427204
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL: Independent validation in a prospective cohort of early stage patients.
    Molica S; Shanafelt TD; Giannarelli D; Gentile M; Mirabelli R; Cutrona G; Levato L; Di Renzo N; Di Raimondo F; Musolino C; Angrilli F; Famà A; Recchia AG; Chaffee KG; Neri A; Kay NE; Ferrarini M; Morabito F
    Am J Hematol; 2016 Nov; 91(11):1090-1095. PubMed ID: 27465919
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patients with chronic lymphocytic leukaemia and clonal deletion of both 17p13.1 and 11q22.3 have a very poor prognosis.
    Greipp PT; Smoley SA; Viswanatha DS; Frederick LS; Rabe KG; Sharma RG; Slager SL; Van Dyke DL; Shanafelt TD; Tschumper RC; Zent CS
    Br J Haematol; 2013 Nov; 163(3):326-33. PubMed ID: 24032430
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dissecting the role of TP53 alterations in del(11q) chronic lymphocytic leukemia.
    Quijada-Álamo M; Pérez-Carretero C; Hernández-Sánchez M; Rodríguez-Vicente AE; Herrero AB; Hernández-Sánchez JM; Martín-Izquierdo M; Santos-Mínguez S; Del Rey M; González T; Rubio-Martínez A; García de Coca A; Dávila-Valls J; Hernández-Rivas JÁ; Parker H; Strefford JC; Benito R; Ordóñez JL; Hernández-Rivas JM
    Clin Transl Med; 2021 Feb; 11(2):e304. PubMed ID: 33634999
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Normal serum protein electrophoresis and mutated IGHV genes detect very slowly evolving chronic lymphocytic leukemia patients.
    Chauzeix J; Laforêt MP; Deveza M; Crowther L; Marcellaud E; Derouault P; Lia AS; Boyer F; Bargues N; Olombel G; Jaccard A; Feuillard J; Gachard N; Rizzo D
    Cancer Med; 2018 Jun; 7(6):2621-2628. PubMed ID: 29745034
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.